



## COVID-19 Research Tools

Defeat the SARS-CoV-2 Variants

InVivoGen



The Journal of  
**Immunology**

This information is current as  
of August 4, 2022.

### The TLR9 Ligand CpG Promotes the Acquisition of *Plasmodium falciparum* -Specific Memory B Cells in Malaria-Naive Individuals

Peter D. Crompton, Marko Mircetic, Greta Weiss, Amy Baughman, Chung-Yu Huang, David J. Topham, John J. Treanor, Iñaki Sanz, F. Eun-Hyung Lee, Anna P. Durbin, Kazutoyo Miura, David L. Narum, Ruth D. Ellis, Elissa Malkin, Gregory E. D. Mullen, Louis H. Miller, Laura B. Martin and Susan K. Pierce

*J Immunol* 2009; 182:3318-3326; ;

doi: 10.4049/jimmunol.0803596

<http://www.jimmunol.org/content/182/5/3318>

**References** This article **cites 32 articles**, 10 of which you can access for free at:  
<http://www.jimmunol.org/content/182/5/3318.full#ref-list-1>

#### Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days\*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*\*average*

**Subscription** Information about subscribing to *The Journal of Immunology* is online at:  
<http://jimmunol.org/subscription>

**Permissions** Submit copyright permission requests at:  
<http://www.aai.org/About/Publications/JI/copyright.html>

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://jimmunol.org/alerts>

*The Journal of Immunology* is published twice each month by  
The American Association of Immunologists, Inc.,  
1451 Rockville Pike, Suite 650, Rockville, MD 20852  
Copyright © 2009 by The American Association of  
Immunologists, Inc. All rights reserved.  
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



# The TLR9 Ligand CpG Promotes the Acquisition of *Plasmodium falciparum*-Specific Memory B Cells in Malaria-Naive Individuals<sup>1</sup>

Peter D. Crompton,<sup>2\*</sup> Marko Mircetic,\* Greta Weiss,\* Amy Baughman,\* Chiung-Yu Huang,<sup>†</sup> David J. Topham,<sup>‡</sup> John J. Treanor,<sup>‡</sup> Iñaki Sanz,<sup>‡</sup> F. Eun-Hyung Lee,<sup>‡</sup> Anna P. Durbin,<sup>§</sup> Kazutoyo Miura,<sup>¶</sup> David L. Narum,<sup>¶</sup> Ruth D. Ellis,<sup>¶</sup> Elissa Malkin,<sup>3¶</sup> Gregory E. D. Mullen,<sup>¶</sup> Louis H. Miller,<sup>¶</sup> Laura B. Martin,<sup>¶</sup> and Susan K. Pierce\*

Despite the central role of memory B cells (MBC) in protective immune responses, little is understood about how they are acquired in naive individuals in response to Ag exposure, and how this process is influenced by concurrent activation of the innate immune system's TLR. In this longitudinal study of malaria-naive individuals, we examined the MBC response to two candidate malaria vaccines administered with or without CpG, a TLR9 ligand. We show that the acquisition of MBC is a dynamic process in which the vaccine-specific MBC pool rapidly expands and then contracts, and that CpG enhances the kinetics, magnitude, and longevity of this response. We observed that the percentage of vaccine-specific MBC present at the time of reimmunization predicts vaccine-specific Ab levels 14 days later; and that at steady-state, there is a positive correlation between vaccine-specific MBC and Ab levels. An examination of the total circulating MBC and plasma cell pools also suggests that MBC differentiate into plasma cells through polyclonal activation, independent of Ag specificity. These results provide important insights into the human MBC response, which can inform the development of vaccines against malaria and other pathogens that disrupt immunological memory. *The Journal of Immunology*, 2009, 182: 3318–3326.

The adaptive immune system encodes the ability to “remember” an initial encounter with an Ag and to respond to that Ag upon reexposure in a rapid and robust fashion for the lifetime of the individual. This phenomenon of immunological memory is a fundamental property of the adaptive immune system and is the basis for all vaccine development. For most vaccines, neutralizing Ab plays a critical role in protective immune responses (1), and thus the mechanisms that underlie the generation and maintenance of humoral memory are of considerable interest. Long-term humoral immunity is encoded in memory B cells (MBC)<sup>4</sup> and long-lived plasma cells (LLPC), which are generated

as a part of the primary immune response (2, 3). LLPC are terminally differentiated cells that reside in the bone marrow and are responsible for the long-term maintenance of serum Ab levels, which play a key role in the initial control of pathogens and their toxins upon reinfection. MBC are capable of mounting an Ag-induced response by proliferating and differentiating into plasma cells (PC), resulting in rapid, high-titer secondary Ab responses upon reexposure to pathogens. Despite the central role of MBC in combating infections, our understanding of the cellular and molecular mechanisms that underlie the generation and maintenance of B cell memory is incomplete. Efforts to develop new vaccines would benefit from a more detailed knowledge of these processes, particularly vaccines against pathogens such as *Plasmodium falciparum* and HIV, which appear to subvert immunological memory (4, 5).

A hallmark of immunological memory is its longevity. The long-lived nature of PC in humans has been inferred from the stability of serum Ab induced by vaccination or infection. Virus-specific Ab levels were shown to be maintained for >60 years after smallpox vaccination (6–8). A recent longitudinal study provided evidence for the remarkable stability of Ab responses following infection, with half-lives ranging from 50 years for varicella-zoster virus (VZV) to >200 years for measles and mumps viruses (9). Recently developed quantitative assays have allowed analyses of the longevity of Ag-specific MBC in immunized individuals. Vaccinia-specific MBC have been detected for >50 years after smallpox vaccination and represented ~0.1% of total circulating MBC (6). These MBC were apparently functional and produced a robust Ab response upon revaccination. MBC specific for a variety of other viral and nonreplicating Ags, including

\*Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852; <sup>†</sup>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; <sup>‡</sup>University of Rochester School of Medicine and Dentistry, Rochester, NY 14642; <sup>§</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205; and <sup>¶</sup>Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852

Received for publication October 28, 2008. Accepted for publication January 3, 2009.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; by contract N01-AI-25460 from the National Institutes of Health (to D.J.T. and J.J.T.); and by UL1 RR024160 from the National Center for Research Resources (to U.R.M.C.).

<sup>2</sup> Address correspondence and reprint requests to Dr. Peter D. Crompton, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook 2 Building, Room 200F, 12441 Parklawn Drive, Rockville, MD 20852. E-mail address: perompton@niaid.nih.gov

<sup>3</sup> Current address: MedImmune, Gaithersburg, MD 20878.

<sup>4</sup> Abbreviations used in this paper: MBC, memory B cells; AMA1-C1, apical membrane Ag 1-combination 1; ASC, Ab-secreting cells; GEE, generalized estimating equations; KLH, keyhole limpet hemocyanin; LLPC, long-lived plasma cell; MSP1<sub>4-2</sub>-C1, merozoite surface protein 1<sub>4-2</sub>-combination 1; PC, plasma cell; PDC, plasmacytoid

dendritic cell; SAC, protein A from *Staphylococcus aureus* Cowan; VZV, varicella-zoster virus 1.

measles, mumps, rubella, EBV, VZV, and tetanus and diphtheria toxins, were also found to be remarkably stable in a recent cross-sectional analysis of adults (9). An inherent limitation to the analysis of MBC in humans has been the restricted access to tissues other than peripheral blood and the unknown relationship between the relative frequency of MBC in the peripheral blood and lymphoid tissue. However, a recent study of individuals decades after smallpox vaccination showed that although most vaccinia-specific MBC were in the spleen, their frequency in the spleen reflected the frequency in peripheral blood (10).

Although the longevity of PC and MBC is a central feature of humoral memory, our understanding of the mechanisms that underlie the maintenance of these cell populations for the lifetime of an individual is only partial. A key question is the role of Ag exposure in maintaining immunological memory in humans. There are several historical examples of the maintenance of Ab-mediated immunity in the absence of Ag exposure, including immunity to measles on the Faroe Islands, yellow fever in the U.S., and polio in remote Eskimo villages (reviewed in Ref. 2). The detection of Ag-specific MBC for >50 years after smallpox vaccination also provides evidence for the persistence of MBC in the absence of Ag (6). If Ag-specific activation is not required to maintain MBC, the question is whether nonspecific polyclonal activation plays a role. One study showed that diphtheria vaccination does not increase the frequency of tetanus-specific MBC (11), suggesting that MBC do not increase in numbers in response to bystander polyclonal activation.

For PC two mechanisms have been proposed to account for their longevity: namely, that they are inherently long-lived or, alternatively, that they are replenished periodically by MBC that differentiate into PC following stimulation with Ag or polyclonal activators, such as TLR ligands and bystander T cell help (12) (reviewed in Ref. 13). That MBC are responsible for replenishing PC is suggested by the correlation observed between tetanus- and measles-specific MBC and their respective Ab levels at steady-state (12). This study also noted a small increase in PC to non-cognate Ags following tetanus toxoid vaccination, an observation the authors interpreted as polyclonal activation and differentiation of nontetanus MBC. Correlations between MBC and Ab levels have also been observed in smallpox- and anthrax-immunized adults (6, 14). A recent study in infants showed an association between MBC and Ab levels 1 mo after immunization with the serogroup C meningococcal conjugate vaccine, and also an association between the number of MBC before a booster vaccination at 5 mo and the Ab levels at 1 year (15). However, correlations between Ab levels and MBC have not always been observed (10, 11, 16), suggesting that LLPC may be regulated independently of MBC. For example, a recent cross-sectional study showed that MBC and serum Ab levels correlated for some but not all Ags (9). Indeed, MBC in individuals with the highest rate of revaccination or latent infections showed the weakest correlation with Ab titers, an indication that LLPC maintenance is not dependent on MBC. Consistent with this is the observation that PC-sparing B cell depletion through rituximab treatment impaired recall Ab responses to some Ags but did not result in significant decreases in serum Ab levels (17–20).

Although several studies have addressed the maintenance of MBC and LLPC, relatively little is known about how they are acquired in humans. Of particular interest in this process is the role of TLR9, a pattern recognition receptor that initiates innate immune responses. TLR9 detects microbial DNA with hypomethylated CpG motifs and in humans is preferentially expressed by plasmacytoid dendritic cells (PDC) and B cells (reviewed in Ref. 21). The net effect of TLR9 activation is the differentiation of Th1 cells

and the induction of IgG isotype switching and Ab secretion. In a hepatitis B vaccine clinical trial the addition of CPG 7909, a B-class CpG oligodeoxynucleotide, accelerated the acquisition of specific Ab and increased peak Ab titers (22, 23). However, the impact of CpG on the MBC response to primary immunization has not been delineated. Here we describe the kinetics of Ag-specific MBC acquisition in naive individuals in response to vaccination with malaria Ags and provide evidence that CPG 7909 enhances this process. This analysis was conducted in the context of two separate clinical trials of two candidate malaria subunit protein vaccines formulated on aluminum hydroxide gel (Alhydrogel), with and without CPG 7909, given to healthy malaria-naive adults (24) ([www.clinicaltrials.gov](http://www.clinicaltrials.gov) no. NCT00320658). We observed that the acquisition of MBC is a highly dynamic process; within 7 days of the second and third vaccinations the vaccine-specific MBC pool first expanded to represent ~3–4% of all IgG<sup>+</sup> MBC in the periphery and then contracted to <1% within 6 mo of the first vaccination. CPG 7909 clearly enhanced the kinetics, magnitude, and longevity of this response. We also describe an Ag-independent effect of vaccination on preexisting MBC that suggests a role of the innate immune system in regulating the behavior of existing B cell memory.

## Materials and Methods

### *Study population and vaccination procedure*

The acquisition of MBC was evaluated in malaria-naive adults enrolled in two separate phase 1 clinical trials of the blood stage malaria vaccine candidates, apical membrane Ag 1-combination 1 (AMA1-C1) and merozoite surface protein 1<sub>42</sub>-combination 1 (MSP1<sub>42</sub>-C1), both formulated on Alhydrogel and mixed with 564 μg of CPG 7909 (24) ([www.clinicaltrials.gov](http://www.clinicaltrials.gov) no. NCT00320658). Both vaccines contained an equal mixture of Ag from two different clones of *P. falciparum* (FVO and 3D7) produced separately as recombinant proteins. Both trials were conducted under Investigational New Drug Applications reviewed by the U.S. Food and Drug Administration, and both were reviewed and approved by the National Institute of Allergy and Infectious Diseases Institutional Review Board and by the Institutional Review Boards at their respective sites and funding agencies. Written informed consent was obtained from all participants. Samples from 40 individuals, 20 from each trial, were randomly selected for analysis, half of whom had been vaccinated with CPG 7909-containing vaccines. Individuals received i.m. vaccinations on days 0, 28, and 56. For the AMA1-C1 trial, individuals received 80 μg of AMA1-C1 protein with the exception of four volunteers in the CPG 7909 group who received 20 μg. Since the dose of AMA1-C1 was not associated with a difference in the magnitude of the AMA1-C1-specific MBC response at any time point ( $p > 0.100$  for all time points), the high- and low-dose groups were analyzed as a single group. For MSP1<sub>42</sub>-C1, all individuals received 80 μg of protein.

### *PBMC isolation, cryopreservation, and recovery*

Peripheral venous blood samples were drawn into heparinized tubes (BD Biosciences). PBMC were isolated from whole blood by Ficoll-Hypaque density gradient centrifugation (Amersham Biosciences) and frozen at 10 million cells/ml in 90% heat-inactivated FBS (Invitrogen) and 10% DMSO (Sigma-Aldrich) using “Mr. Frosty” freezing containers (VWR International) to control the rate of freezing to  $-80^{\circ}\text{C}$  for 24 h before transfer to liquid nitrogen. Liquid nitrogen storage freezers were connected to an automatic fill system and were outfitted with an external temperature alarm system. For each individual, frozen PBMC from all available time points were thawed and assayed simultaneously. PBMC were rapidly thawed in a  $37^{\circ}\text{C}$  water bath and then added to complete media (RPMI 1640 plus L-glutamine (Invitrogen) supplemented with 10% heat-inactivated FBS, penicillin (10,000 IU/ml), streptomycin (10,000 μg/ml; Invitrogen), and 2-ME (50 μM; Invitrogen)) warmed to  $37^{\circ}\text{C}$ . Cells were washed, resuspended in complete media, and counted using trypan blue (BioWhittaker) dye exclusion to detect viable cells.

### *Multiparameter flow cytometry and cell sorting*

To verify that the ELISPOT assay specifically detects MBC, PBMC obtained from malaria-naive healthy donors at the National Institutes of Health blood bank were isolated from elutriated mononuclear cells by Ficoll-Hypaque density gradient centrifugation. Cells were washed in PBS


and platelets were removed by low-speed centrifugation through FBS. Cells were stained with fluorescently-labeled Ab to CD19 (PE-Cy5.5; Caltag Laboratories), CD27 (PE; Caltag Laboratories), and CD38 (allophycocyanin; BD Biosciences) and sorted on a FACSAria cell-sorting system (BD Biosciences). B cell subsets were defined as naive ( $CD19^+CD27^-$ ), memory ( $CD19^+CD27^+CD38^-$ ), and plasma ( $CD19^+CD27^+CD38^{+++}$ ) cells. Sorted B cells were cultured in triplicate with or without non-B cells in complete media or stimulation media (see below) for 5 days, washed in complete media warmed to  $37^\circ\text{C}$ , and transferred directly onto 96-well filter-bottom ELISPOT plates (Millipore Multiscreen-HA) prepared for the MBC ELISPOT assay with IgG-specific capture Ab and Ags, as described below.

The kinetics of the PC response to vaccination were examined in a subset of individuals from the AMA1-C1/Alhydrogel study. The lymphocyte fraction of peripheral venous blood samples was separated by Ficoll-Hypaque density gradient centrifugation, and  $1 \times 10^6$  fresh PBMC were placed in each well of a 96-well plate and stained at  $4^\circ\text{C}$  for 30 min with fluorescently labeled Ab to CD19 (PE-Cy5.5; Invitrogen), CD3 (Alexa 405; Invitrogen), CD27 (PE; Invitrogen), CD38 (PE-Cy7; Invitrogen), and IgD (FITC; Invitrogen) and then washed with PBS. Stained cells were resuspended in PBS, fixed with 1% paraformaldehyde, and analyzed on a BD LSR II (BD Biosciences). Data were processed by FlowJo software (Tree Star). To visualize the B cell response to vaccination in the peripheral blood, a broad lymphocyte gate was applied to the flow cytometry data, and then  $CD3^-CD19^+$  events were selected and analyzed for expression of CD27 and CD38. Contour and density plots were used to set uniform regions around  $CD27^+CD38^+$  and  $CD27^+CD38^{+++}$  events to calculate percentages (among the  $CD3^-CD19^+$  cells).

#### Memory B cell ELISPOT assay

Ag-specific MBC and total IgG<sup>+</sup> MBC were quantified by an assay in which MBC were stimulated in vitro to differentiate into Ab-secreting cells (ASC) (25). One million thawed PBMC were placed in each well of a 24-well plate (Corning) containing 1 ml of complete media alone or complete media plus a cocktail of polyclonal activators, which included 2.5  $\mu\text{g/ml}$  of CpG oligodeoxynucleotide-2006 (Operon Technologies), SAC at 1/10,000 dilution (Sigma-Aldrich), and pokeweed mitogen at 1/100,000 dilution (Sigma-Aldrich). Cells were kept at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  incubator for 5 days, washed twice with complete media warmed to  $37^\circ\text{C}$ , counted, and distributed onto 96-well plates that had been prepared for the MBC ELISPOT assay, as described below.

For the AMA1-C1- and MSP1<sub>42</sub>-C1-specific ELISPOT assays, filter-bottom 96-well plates (Millipore Multiscreen-HA) were coated with a 1:1 mixture of AMA1-C1-FVO (2.5  $\mu\text{g/ml}$ ) and AMA1-C1-3D7 (2.5  $\mu\text{g/ml}$ ) or a 1:1 mixture of MSP1<sub>42</sub>-C1-FVO (2.5  $\mu\text{g/ml}$ ) and MSP1<sub>42</sub>-C1-3D7 (2.5  $\mu\text{g/ml}$ ) for a final concentration of 5  $\mu\text{g/ml}$  in PBS (KD Medical). These recombinant proteins were clinical grade and lot matched to the vaccines administered to the study participants. For the detection of total IgG-secreting cells, wells were coated with polyvalent goat anti-human IgG (Caltag Laboratories) at 10  $\mu\text{g/ml}$  in PBS. As a control, wells were coated with the irrelevant Ag keyhole limpet hemocyanin (KLH; Pierce) at 2.5  $\mu\text{g/ml}$  in PBS. Plates were incubated overnight at  $4^\circ\text{C}$ . They were then washed once with PBS-0.05% Tween 20 (Thermo Fisher Scientific), and three times with PBS. Plates were blocked with 1% BSA (Sigma-Aldrich) in RPMI 1640 for 2 h at  $37^\circ\text{C}$ . Stimulated PBMC resuspended in 200  $\mu\text{l}$  of fresh complete media were distributed onto coated 96-well plates in triplicate as follows: AMA1-C1- and MSP1<sub>42</sub>-C1-coated wells at  $5 \times 10^5$  cells/well, and anti-human IgG-coated wells at  $1 \times 10^4$  cells/well. Both were followed by serial 2-fold dilutions. As controls, stimulated PBMC resuspended in 200  $\mu\text{l}$  of fresh complete media were distributed onto KLH-coated wells at  $2 \times 10^4$  cells/well and unstimulated PBMC at  $2 \times 10^4$  cells/well on anti-human IgG-coated wells. Plates were kept at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  incubator for 5 h and then washed four times with PBS and four times with PBS-0.05% Tween 20. The detection Ab, goat anti-human IgG Fc-alkaline phosphatase (Jackson ImmunoResearch Laboratories) diluted in PBS-0.05% Tween 20 with 1% FBS, was added to wells and incubated overnight at  $4^\circ\text{C}$ . Plates were washed four times with PBS-0.05% Tween 20, three times with PBS, and three times with distilled water before developing with the substrate BCIP/NBT (Calbiochem). Spots were counted with the ImmunoSpot series 4 analyzer (Cellular Technology). Laboratory investigators were blinded to the CPG 7909 status of study participants. Ag-specific MBC data are expressed as follows: frequency of Ag-specific MBC per million PBMC (after 5-day culture)/frequency of Ig-secreting MBC per million PBMC (after 5-day culture)  $\times 100$ .



**FIGURE 1.** Only MBC differentiate into ASC in response to polyclonal activators in vitro. The lymphocyte fractions from elutriated PBMC obtained from healthy volunteers were subjected to fluorescence-activated cell sorting based on the expression of CD19, CD27, and CD38 into naive B cells, MBC, and PC. Subpopulations were cultured for 5 days in the presence of the polyclonal activators pokeweed mitogen, SAC, and CpG (stimulated) or in their absence (unstimulated). The total number of IgG<sup>+</sup> ASC was quantified in an ELISPOT assay using human IgG-specific Ab to capture secreted IgG. Shown are the mean numbers of IgG<sup>+</sup> ASC expressed as a percentage of the number of cells used in the ELISPOT assay after 5 days in culture. Error bars indicate SEM ( $n = 3$  independent experiments).

#### ELISA

The ELISA protocol and Ab data from the AMA1-C1 trial were published previously (24). ELISA data shown represent the mean ELISA units for AMA1-C1-FVO and AMA1-C1-3D7 and for MSP1<sub>42</sub>-C1-FVO and MSP1<sub>42</sub>-C1-3D7, respectively. It is noteworthy that there was a strong correlation between AMA1-C1-FVO and AMA1-C1-3D7 titers (24), as well as for MSP1<sub>42</sub>-C1-FVO and MSP1<sub>42</sub>-C1-3D7 titers (www.clinicaltrials.gov no. NCT00320658).

#### Data analysis

The correlation between different continuous measures was determined by using the Spearman correlation coefficient. To account for the correlation among multiple measurements for the same subject, the generalized estimating equations (GEE) method (26) was employed to study the association between continuous outcomes and covariates of interest. The GEE method yields valid inferential results even when the correlation structure of the repeated measurements is not correctly specified. GEE models with the study day as a categorical covariate were used to compare repeated measurements with the baseline measurement within the same group. Comparisons between the two groups were conducted by using GEE models with the study day indicators and the CPG 7909 group indicator, as well as their interaction terms as covariates. An “exchangeable” correlation structure was used as the working assumption for all GEE analyses. All  $p$  values were two-sided, and  $p$  values of  $<0.05$  were considered to be statistically significant. Data analyses were performed with STATA version 10.0 (StataCorp) and GraphPad Prism version 5.01 for Windows (GraphPad Software).

## Results

#### Verification of the specificity of the MBC ELISPOT assay

MBC were quantified in peripheral blood samples by the method of Crotty et al. (25), which is based on the differentiation of MBC ( $CD19^+CD27^+$ ) but not naive B cells ( $CD19^+CD27^-$ ) into ASC in response to polyclonal activators. To verify that this assay specifically detects MBC, the lymphocyte fraction from elutriated PBMC obtained from healthy volunteers was separated by fluorescence-activated cell sorting into the following subpopulations:  $CD19^-$  non-B cells,  $CD19^+CD27^-$  naive B cells,  $CD19^+CD27^+$  MBC, and  $CD27^+CD38^{+++}$  PC. Each subpopulation was stimulated with polyclonal activators for 5 days and assayed for IgG-secreting cells, which were only detected in cultures of  $CD19^+CD27^+$  MBC (Fig. 1).

Table I. Sample size and mean vaccine-specific MBC percentage by vaccine type, CpG group, and study day

Study Day	AMA1-C1 <sup>a</sup>				MSP1 <sub>42</sub> -C1 <sup>b</sup>			
	Without CPG 7909		With CPG 7909		Without CPG 7909		With CPG 7909	
	n	% MBC <sup>c</sup> (95% CI)	n	% MBC (95% CI)	n	% MBC (95% CI)	n	% MBC (95% CI)
0 <sup>d</sup>	10	0.03 (-0.16, 0.22)	10	0.02 (-0.77, 0.80)	11	0.01 (-0.05, 0.07)	9	0.01 (-0.38, 0.39)
3 <sup>e</sup>	10	0.02 (-0.21, 0.26)	8	0.04 (-0.74, 0.82)				
7	10	0.01 (-0.20, 0.21)	9	0.05 (-0.73, 0.83)	11	0.01 (-0.05, 0.07)	9	0.004 (-0.38, 0.39)
28 <sup>d</sup>	10	0.02 (-0.19, 0.23)	9	0.09 (-0.76, 0.94)	10	0.04 (-0.02, 0.10)	9	0.07 (-0.32, 0.45)
31	8	0.03 (-0.18, 0.24)	9	0.54 (-0.27, 1.36)	11	0.04 (-0.01, 0.10)	9	0.06 (-0.32, 0.44)
35 <sup>e</sup>	10	0.09 (-0.14, 0.32)	8	2.94* (2.12, 3.75)				
56 <sup>d</sup>	10	0.13 (-0.09, 0.35)	8	1.79* (0.97, 2.60)	10	0.10* (0.04, 0.15)	9	0.97* (0.59, 1.35)
59	8	0.11 (-0.11, 0.33)	9	1.58* (0.72, 2.43)	10	0.08* (0.02, 0.14)	8	1.20* (0.80, 1.60)
63 <sup>e</sup>	7	0.26 (0.04, 0.48)	8	3.45* (2.55, 4.35)				
84 <sup>e</sup>	8	0.75* (0.51, 0.98)	7	1.52* (0.67, 2.37)				
140	10	0.59* (0.37, 0.81)	9	1.44* (0.62, 2.26)	11	0.13* (0.08, 0.19)	9	0.83* (0.45, 1.21)
236 <sup>e</sup>	7	0.15 (-0.21, 0.50)	4	1.41* (0.45, 2.37)				

<sup>a</sup> Missing data due to technical error (4.6%), individual lost to follow-up (5.8%), or unavailability of sample (7.5%).

<sup>b</sup> Missing data due to unavailability of sample (2.9%).

<sup>c</sup> Percentage vaccine-specific MBC and 95% CIs are obtained by fitting GEE models described in *Materials and Methods*.

<sup>d</sup> Vaccination day.

<sup>e</sup> Samples collected for AMA1-C1 trial only.

\*,  $p < 0.05$  vs study day 0.


### The acquisition of MBC in naive individuals

To determine the kinetics, magnitude, and longevity of the MBC response to primary immunization, as well as the impact of TLR9 activation on this process, we examined the acquisition of *P. falciparum*-specific MBC in malaria-naive individuals enrolled in two phase 1 clinical trials of two malaria subunit protein vaccine candidates, AMA1-C1 and MSP1<sub>42</sub>-C1. Both AMA1-C1 and MSP1<sub>42</sub>-C1 were formulated on Alhydrogel with and without CPG 7909. Samples from 40 individuals, 20 from each trial, were randomly selected for analysis, half of whom had been vaccinated with CPG 7909-containing vaccines. Individuals were vaccinated on days 0, 28, and 56, and peripheral blood samples were collected at the times shown in Table I. For both trials the mean viability of PBMC after thawing was similar in the CPG and non-CPG groups, that is, 92.3% and 95.9%, respectively ( $p = 0.165$ ).

In the AMA1-C1 trial, before vaccination (baseline) the mean percentage of IgG<sup>+</sup> MBC that were AMA1-C1-specific was not significantly different from the irrelevant control Ag KLH (0.02% AMA1-C1-specific MBC vs 0.07% KLH-specific MBC;  $p = 0.44$ ). The lower limit of detection of the ELISPOT assay in this study is the lowest percentage of Ag-specific spots that can be distinguished from the average percentage of spots on wells coated with KLH. As per Crotty et al. (25), by using best estimates of the relevant parameters ( $1.25 \times 10^6$  PBMC per ml of blood; B cells are 10% of PBMC; MBC are 30% of B cells; IgG<sup>+</sup> MBC are 50% of MBC), 0.07% translates into a lower limit of detection in this study of  $\sim 13$  Ag-specific IgG<sup>+</sup> MBC per ml of blood.


Compared with baseline, individuals receiving AMA1-C1/Alhydrogel without CPG 7909 did not have a statistically significant increase in AMA1-C1-specific MBC until 28 days after the third vaccination, at which point 0.75% of all IgG<sup>+</sup> MBC were AMA1-C1-specific ( $p < 0.001$  vs baseline; Fig. 2, upper panel). AMA1-C1-specific MBC remained above baseline at 0.59% 84 days after the third vaccination ( $p < 0.001$  vs baseline) and then decreased to baseline levels  $\sim 100$  days later ( $p = 0.57$  vs baseline). At all other time points, the percentage of AMA1-C1-specific MBC did not differ significantly from baseline levels. Thus, vaccination with AMA1-C1/Alhydrogel without CPG 7909 induced AMA1-C1-specific MBC only after repeated immunization, and these MBC did not persist at detectable levels 6 mo after the last vaccination.

In contrast, a dramatic increase in AMA1-C1-specific MBC was observed in individuals vaccinated with AMA1-C1/Alhydrogel plus CPG 7909. In this group AMA1-C1-specific MBC appeared in the peripheral circulation 3 days after the second vaccination and peaked 4 days later, at 2.94% of all IgG<sup>+</sup> MBC, and then decreased to 1.79% 21 days later on the day of the third vaccination (Fig. 2, upper panel). Seven days after the third vaccination the percentage peaked again at 3.45% and then contracted to 1.41% by the end of the study (236 days after the first vaccination), a rate of decline of  $\sim 0.4\%$  per month. AMA1-C1-specific MBC



**FIGURE 2.** In malaria-naive individuals, CPG 7909 enhances the kinetics, magnitude, and longevity of the AMA1-C1- and MSP1<sub>42</sub>-C1-specific MBC response to vaccination. *Upper*, Individuals vaccinated with AMA1-C1/Alhydrogel with CPG 7909 (red circles;  $n = 10$ ) or without CPG 7909 (blue squares;  $n = 10$ ). *Lower*, Individuals vaccinated with MSP1<sub>42</sub>-C1/Alhydrogel with CPG 7909 (red circles;  $n = 9$ ) or without CPG 7909 (blue squares;  $n = 11$ ). Data are reported as mean percentage  $\pm$  SEM. The sample size at each time point is given in Table I.


**FIGURE 3.** The AMA1-C1- and MSP1<sub>42</sub>-C1-specific Ab response mirrors the corresponding MBC response and is enhanced by CPG 7909. The Ab levels (red circles) determined by ELISA are given for individuals vaccinated with AMA1-C1/Alhydrogel (*left*) or MSP1<sub>42</sub>-C1/Alhydrogel (*right*) without CPG 7909 (*upper*) or with CPG 7909 (*lower*). Ab levels for each vaccine are the average of the 3D7 and FVO responses. The corresponding percentages of Ag-specific MBC are given for comparison (blue squares). Data are reported as mean percentage (MBC) or mean ELISA units (Ab)  $\pm$  SEM. The sample size at each time point is given in Table I.




were significantly increased over baseline at all time points beginning 1 wk after the second vaccination through the end of the study period ( $p < 0.010$  vs baseline). Compared with individuals who received AMA1-C1/Alhydrogel without CPG 7909, the mean percentage of AMA1-C1-specific MBC was higher at all time points after vaccination, reaching statistical significance on days 35, 56, 59, and 63 (all  $p < 0.010$ ) and marginal statistical significance on days 140 and 236 ( $p = 0.092$  and  $p = 0.061$ , respectively). Thus, the inclusion of CPG 7909 enhanced the kinetics, magnitude, and longevity of the AMA1-C1-specific MBC response.

CPG 7909 had a similar impact on the acquisition of MBC in response to vaccination with MSP1<sub>42</sub>-C1/Alhydrogel (Fig. 2, *lower panel*). Compared with the AMA1-C1 trial, fewer PBMC samples were collected in the MSP1<sub>42</sub>-C1 trial, namely, on the day of each vaccination (days 0, 28, and 56), 7 days after the first

vaccination, 3 days after the second and third vaccinations, and on day 140 (Table I). Before vaccination (baseline) the mean percentage of IgG<sup>+</sup> MBC that were MSP1<sub>42</sub>-C1-specific was not significantly different from KLH (0.01% MSP1<sub>42</sub>-C1-specific MBC vs 0.07% KLH-specific MBC;  $p = 0.89$ ). Vaccination with MSP1<sub>42</sub>-C1/Alhydrogel without CPG 7909 did not generate statistically significant levels of MSP1<sub>42</sub>-C1-specific MBC until 28 days after the second vaccination, reaching 0.10% of all IgG<sup>+</sup> MBC ( $p = 0.005$  vs baseline). The percentage of MSP1<sub>42</sub>-C1-specific MBC remained greater than baseline at 3 and 84 days after the third vaccination (day 3 after third vaccination, 0.08% ( $p = 0.022$  vs baseline); day 84 after third vaccination, 0.13% ( $p < 0.001$  vs baseline)). Vaccination with MSP1<sub>42</sub>-C1/Alhydrogel with CPG 7909, by contrast, generated a mean percentage of MSP1<sub>42</sub>-C1-specific MBC of 0.97% on the day of the third vaccination ( $p <$



**FIGURE 4.** The level of Ag-specific MBC at the time of booster vaccination predicts the Ab response 14 days later. For AMA1-C1 the percentage of Ag-specific MBC at the time of the second and third vaccinations predicted the levels of AMA1-C1 Ab 14 days later (A, second vaccination,  $r = 0.70$ ,  $p = 0.003$ ; B, third vaccination,  $r = 0.87$ ,  $p < 0.001$ ). A similar relationship was observed for the MSP1<sub>42</sub>-C1 vaccine (C, second vaccination,  $r = 0.47$ ,  $p = 0.057$ ; D, third vaccination,  $r = 0.83$ ,  $p < 0.001$ ). At these time points corresponding ELISPOT and ELISA data were available for 15 individuals in the AMA1-C1 trial and 17 individuals in the MSP1<sub>42</sub>-C1 trial. Ab levels for each vaccine are the average of the 3D7 and FVO responses.



**FIGURE 5.** At steady-state, levels of Ag-specific MBC and Ab are highly correlated. To determine the correlation between Ag-specific MBC and Ab titers closer to steady-state, the last time point with corresponding ELISPOT and ELISA data (AMA1-C1 trial day 236, MSP1<sub>42</sub>-C1 trial day 140) was analyzed in cross-section. A positive correlation between Ag-specific MBC and Ab titers was observed in both trials at steady-state (AMA1-C1,  $r = 0.80$ ,  $p = 0.014$ ; MSP1<sub>42</sub>-C1,  $r = 0.86$ ,  $p < 0.001$ ). Corresponding ELISPOT and ELISA data were available for 9 individuals in the AMA1-C1 trial and 19 individuals in the MSP1<sub>42</sub>-C1 trial at this time point. Ab levels for each vaccine are the average of the 3D7 and FVO responses.


0.001 vs baseline) and remained at 1.20% and 0.83% at 3 and 84 days after the third vaccination ( $p < 0.001$  and  $p = 0.001$ , respectively, vs baseline). Because samples were not collected 7


days after the second and third vaccinations in the MSP1<sub>42</sub>-C1 trial, we do not know whether the MBC percentage reached higher peak levels, as observed in the AMA1-C1 trial. Thus, despite the difference in the ability of AMA1-C1 and MSP1<sub>42</sub>-C1 to generate vaccine-specific MBC in the absence of CPG 7909, the CPG 7909-containing vaccines resulted in similar levels of vaccine-specific MBC at the end of each study, that is, ~1% of total IgG<sup>+</sup> MBC, compared with ~0.1% for the non-CPG 7909-containing vaccines.

*The acquisition of MBC mirrors and predicts Ab responses*

In humans the role that MBC play in maintaining Ab titers and LLPC remains unclear. The longitudinal design of this study allowed an examination of the relationship between MBC and Ab titers in a manner not possible in cross-sectional analyses. In general we observed that vaccination with either AMA1-C1 or MSP1<sub>42</sub>-C1 on Alhydrogel generated Ab levels that correlated with the vaccine-specific MBC response, and for both vaccines the inclusion of CPG 7909 induced higher levels of Ab and MBC (Fig. 3). We also observed that the percentage of AMA1-C1-specific MBC on the day of the second and third vaccinations (days 28 and 56) was highly correlated with the levels of AMA1-C1 Abs 14 days later (days 42 and 70) (Fig. 4A, second vaccination,  $r = 0.70$ ,  $p = 0.003$ ; Fig. 4B, third vaccination,  $r = 0.87$ ,  $p < 0.001$ ). Most of the Ab response likely represents the differentiation of MBC into short-lived PC given the rapid decline in titers that followed. In the MSP1<sub>42</sub>-C1 trial we observed a similar relationship between MBC at the time of revaccination and Ab titers 14 days later in the MSP1<sub>42</sub>-C1 trial (Fig. 4C, second vaccination,  $r = 0.47$ ,  $p = 0.057$ ; Fig. 4D, third vaccination,  $r = 0.83$ ,  $p < 0.001$ ). To determine the relationship between Ag-specific MBC and Ab titers at steady-state (~3 and 6 mo after the last MSP1<sub>42</sub>-C1 and AMA1-C1 vaccination, respectively), the last time point with corresponding ELISPOT and ELISA data was analyzed in cross-section. We observed a positive correlation between Ag-specific MBC and Ab titers in both trials (Fig. 5A, AMA1-C1,  $r = 0.80$ ,  $p = 0.003$ ; Fig. 5B, MSP1<sub>42</sub>-C1,  $r = 0.86$ ,  $p < 0.001$ ). Since LLPC are the likely source of Ab titers at this later time point, the correlation between MBC and Ab titers suggests that the maintenance of LLPC may be linked to MBC.

**FIGURE 6.** Vaccination appears to have an Ag-independent effect on the total IgG<sup>+</sup> MBC pool. Shown is the total IgG<sup>+</sup> MBC response expressed as the mean frequency for individuals immunized with AMA1-C1/Alhydrogel (left) or MSP1<sub>42</sub>-C1/Alhydrogel (right) without CPG 7909 (upper) or with CPG 7909 (lower). Days on which there was a statistically significant ( $p < 0.05$ ) decrease in the total IgG<sup>+</sup> MBC frequency, as compared with the total IgG<sup>+</sup> MBC frequency on the day of the preceding vaccination, are indicated with an asterisk. For AMA1-C1 there were 10 individuals in both the non-CPG 7909 and CPG 7909 groups. For MSP1<sub>42</sub>-C1 there were 11 individuals in the non-CPG 7909 group and 9 individuals in the CPG 7909 group. Note that x-axis intervals are not proportional to the time intervals indicated.





**FIGURE 7.** Vaccination has an Ag-independent effect on the total PC pool. Shown is the CD27<sup>+</sup>CD38<sup>+++</sup> PC response expressed as the mean percentage of CD3<sup>-</sup>CD19<sup>+</sup> B cells for individuals immunized with AMA1-C1/Alhydrogel without CPG 7909 (*upper*) or with CPG 7909 (*lower*). Days on which there was a statistically significant ( $p < 0.05$ ) increase in the percentage of PC, as compared with the PC percentage on the day of the preceding vaccination, are indicated with an asterisk. There were three individuals in the non-CPG 7909 group and eight individuals in the CPG 7909 group available for analysis. Due to the small sample size in the non-CPG 7909 group, a statistical test was not done. Note that x-axis intervals are not proportional to the time intervals indicated.

#### Vaccination influences MBC and PC independently of Ag specificity

An examination of total IgG<sup>+</sup> MBC circulating in the periphery showed that vaccination affected this population independently of Ag (Fig. 6). Vaccination with AMA1-C1/Alhydrogel plus CPG 7909 was associated with a decrease in the frequency of IgG<sup>+</sup> MBC 3 days after each vaccination, followed by a gradual return to baseline (Fig. 6, *lower left*), although the decrease was only statistically significant after the third vaccination ( $p = 0.012$ ). At the same time points, the frequency of IgG<sup>+</sup> MBC in those vaccinated with AMA1-C1/Alhydrogel without CPG 7909 did not show a consistent response (Fig. 6, *upper left*). Vaccination with MSP1<sub>42</sub>-C1 with or without CPG 7909 was associated with a decrease in the frequency of IgG<sup>+</sup> MBC 7 days after the first vaccination, and 3 days after the second and third vaccinations, followed by a return to baseline (Fig. 6, *upper and lower right*). The decrease was statistically significant after the third vaccination in the MSP1<sub>42</sub>-C1 with CPG 7909 group ( $p = 0.018$ ), and after the first and third vaccinations in the MSP1<sub>42</sub>-C1 without CPG 7909 group ( $p = 0.021$  and  $p = 0.037$ , respectively). Thus, MBC appear to transiently leave the circulation after vaccination. To determine whether there was a concomitant increase in total PC numbers indicating a polyclonal activation of MBC, fresh PBMC from a subset of individuals in the AMA1-C1 study were analyzed by flow cytometry (fresh PBMC from the MSP1<sub>42</sub>-C1 trial were not available). Irrespective of the CPG 7909 status, 3 days after the second and third vaccination with AMA1-C1/Alhydrogel, there was an increase in CD27<sup>+</sup>CD38<sup>+++</sup> PC as a percentage of total CD3<sup>-</sup>CD19<sup>+</sup> B cells (Fig. 7). The increase was statistically significant after the second vaccination in the CPG 7909 group ( $p <$

0.01). Thus it appears that vaccination with adjuvant-containing vaccines has the potential to influence MBC through polyclonal activation, independently of Ag, and that this activation may drive the differentiation of MBC into PC (3).

#### Discussion

B cell memory plays a central role in conferring protective immunity to many infectious diseases for which there are effective vaccines, and yet little is known about the generation of B cell memory in humans. In this longitudinal study we examined the effect of vaccination on MBC generation in naive individuals and determined the impact of TLR9 activation on this process in vivo. The results presented herein offer new insights into the kinetics of this process and provide evidence that the innate immune receptor TLR9 plays a significant role not only in the generation of MBC in naive individuals but also in controlling the behavior of existing MBC. For the two protein subunit malaria vaccine candidates, AMA1-C1 and MSP1<sub>42</sub>-C1, the inclusion of CPG 7909 had a dramatic effect, resulting in a more rapid acquisition of vaccine-specific MBC, in greater numbers, that persisted longer.

The longitudinal design of this study permitted a detailed characterization of the kinetics of MBC generation and maintenance in response to primary and secondary vaccinations. The capacity for a detailed characterization was most apparent in the analysis of the AMA1-C1 vaccine trial in which PBMC samples were collected at several time points after each vaccination. We observed that AMA1-C1-specific MBC peaked in the peripheral circulation 7 days after the second and third vaccinations, representing ~3–4% of the total IgG<sup>+</sup> MBC pool. Although it has been reported for diphtheria vaccination that the magnitude of the peak MBC response decreased with each booster immunization (11), we did not observe a significant difference between peaks in this study (day 35 CPG 7909 group, 2.94% (95% CI, 2.12–3.75) vs day 63 CPG 7909 group, 3.45% (95% CI, 2.44–4.35);  $p = 0.328$ ). The differences between the studies may be due to the length of time between vaccination or to the efficacy of the vaccines themselves. It is of interest that the second AMA1-C1 vaccination generated AMA1-C1-specific MBC at levels comparable to those observed after influenza (27, 28) and smallpox (6) booster vaccination. Irrespective of CPG 7909 status, the rate of decline of AMA1-C1-specific MBC was ~0.4% per month. If this rate held steady, within 2 years the level of AMA1-C1-specific MBC would approach pre-immune levels in the CPG 7909 group. However, we do not know whether, or at what level, the Ag-specific MBC pool reaches equilibrium. In a cross-sectional study 18 mo after smallpox vaccination, Ag-specific MBC, as a percentage of the total IgG<sup>+</sup> MBC, decreased to 0.1% from a peak of 1% 14 days after vaccination (6). Similarly, in individuals receiving influenza booster vaccinations, influenza-specific MBC increased from low levels before vaccination to 8.2% of IgG<sup>+</sup> MBC 14 days after vaccination, and then declined rapidly to <1% 80 days postvaccination (27). Based on these observations, AMA1-C1-specific MBC would be expected to reach equilibrium at ~0.3% within a year after the final vaccination.

Although TLR9 expression is known to be low in naive B cells and constitutively high in MBC (29), the impact of this differential expression on the in vivo responsiveness to CpG in humans at the cellular level is not known. As measured by the MBC response, we observed no effect of CPG 7909 on primary immunization with AMA1-C1 or MSP1<sub>42</sub>-C1, suggesting that CPG 7909 had little effect on naive B cells directly, or indirectly through TLR9-expressing PDC. However, once generated by primary immunization, TLR9-expressing Ag-specific MBC responded dramatically to secondary immunization in the presence of CPG 7909. Although



the relative impact of TLR9 activation in PDC vs MBC on the secondary response in vivo is not known, it is clear from the results of our in vitro experiments (Fig. 1) that purified MBC differentiate into ASC upon TLR9 activation, as has been shown by others (25).

The mechanisms underlying the apparent expansion and contraction of circulating Ag-specific MBC still need to be elucidated. The contraction phase may represent migration of MBC to lymphoid tissue where newly generated MBC compete for limited homeostatic niches in the MBC compartment. Alternatively, in a manner analogous to T cell Ag-driven expansion and contraction, contraction may represent an activation-induced cell death phenomenon (30). What remains unknown is which factors control the magnitude of the peak response and the subsequent steady-state level.

The results presented herein also address the controversy surrounding the relationship between MBC, LLPC, and serum Ab levels. In general, we observed a positive correlation between the magnitude of the vaccine-specific MBC response and Ab titers. We also observed that the percentage of vaccine-specific MBC present at the time of the second and third vaccinations predicted Ab titers 2 wk later. Most of this Ab was likely produced by short-lived PC given the rapid decline in titers that followed. Similar results were recently reported for infants immunized with the serogroup C meningococcal conjugate vaccine in which the frequency of specific MBC at the time of boosting correlated with postvaccination titers (15). However, the Ab titers we observed closer to steady-state (~3 and 6 mo after the last MSP1<sub>42</sub>-C1 and AMA1-C1 vaccination, respectively) were likely produced by LLPC, and thus the correlation between MBC and Ab titers at steady-state suggests that the maintenance of LLPC may be linked to MBC. The cellular and molecular natures of this relationship remain poorly understood.

In addition to the Ag-specific induction of MBC, we observed an ~2-fold Ag-independent decrease in the frequencies of total IgG<sup>+</sup> MBC in circulation 3 days after the majority of vaccinations. This drop may reflect the migration of MBC into lymphoid tissues, apoptosis of MBC, differentiation of MBC into ASC, or a combination thereof. The concurrent increase in CD27<sup>+</sup>CD38<sup>+++</sup> PC we observed 3 days after the second and third vaccinations in the AMA1-C1/Alhydrogel study suggests that the decline in MBC is due in part to their differentiation into PC. In a separate phase I study of AMA1-C1/Alhydrogel without CPG 7909, we observed a similar increase in PC 3 days after vaccination (unpublished). That polyclonal activation can drive the differentiation of MBC into PC is supported by other studies that have examined the Ag-independent effects of vaccination on PC. Bernasconi et al. observed an increase in ASC directed against *Toxoplasma gondii* and measles 6 days after vaccination with tetanus toxoid (12). These authors attributed this to the polyclonal activation and differentiation of all MBC into PC. Odendahl et al. also observed an increase in circulating ASC of unknown specificity 6 days after vaccination with tetanus toxoid, but interpreted the ASC to be LLPC displaced from the bone marrow by newly generated tetanus-specific PC that better competed for bone marrow PC niches (31). However, a recent study showed that up to a third of circulating ASC appearing after influenza vaccination were not vaccine-specific, and had recently divided, ruling out the possibility that these were LLPC displaced from the bone marrow (10). Collectively, these findings are consistent with a model in which the decrease in total IgG<sup>+</sup> MBC (which we observed after vaccination) is due in part to their polyclonal activation and differentiation into PC (3).

An important question raised by these observations is the nature of the polyclonal activation of MBC in vivo. For the AMA1-C1 vaccine, CPG 7909 was required to induce a consistent decrease in

total IgG<sup>+</sup> MBC, presumably as a result of direct and/or indirect TLR9 signaling in MBC or PDC, respectively. However, for the MSP1<sub>42</sub>-C1 vaccine, a decrease in total IgG<sup>+</sup> MBC was observed in the absence of CPG 7909, presumably due in large part to the alum adjuvant. Recently, alum has been shown to activate an intracellular innate immune response through the Nalp3 inflammasome and to direct Ab responses by mechanisms that, although incompletely understood, likely involve activation of Th2 cells (32). Why AMA1-C1/Alhydrogel without CPG 7909 was not associated with a decrease in total IgG<sup>+</sup> MBC is unclear, but this may reflect a complex interplay between Ag-specific and polyclonal responses. Future studies might explore how activation of TLRs or inflammasomes influences MBC behavior.

The results of this study also provide an important baseline for further investigation of the B cell response to malaria vaccine candidates and natural infection with *P. falciparum*, the most lethal of human malaria species. Results of seroepidemiological studies in malaria endemic areas indicate that humoral immunity to malaria in response to *P. falciparum* infection is slow to develop, incomplete, and short-lived, all of which suggest that *P. falciparum* may have evolved mechanisms to subvert the generation and/or maintenance of immunological memory (4). It will therefore be of interest to compare the B cell response at the cellular level to candidate malaria vaccines in those with no exposure to *P. falciparum*, as in this study, to those living in a malaria endemic area. To that end we are performing similar analyses in individuals enrolled in phase 1 clinical trials of candidate malaria vaccines in Mali. We are also conducting longitudinal studies in Mali (33) to understand the mechanisms that underlie protective immunity to malaria and how *P. falciparum* may modulate this response. An improved understanding of the B cell response to malaria vaccine candidates and natural *P. falciparum* infection can help guide the development of vaccines that provide sustained protection against this important pathogen.

## Acknowledgments

We sincerely thank the volunteers that participated in this study. We also thank the trial site staff, as well as Jane Baer for her assistance in processing blood samples.

## Disclosures

The authors have no financial conflicts of interest.

## References

- Plotkin, S. A. 2008. Vaccines: correlates of vaccine-induced immunity. *Clin. Infect. Dis.* 47: 401–409.
- Crotty, S., and R. Ahmed. 2004. Immunological memory in humans. *Semin. Immunol.* 16: 197–203.
- Lanzavecchia, A., N. Bernasconi, E. Traggiai, C. R. Ruprecht, D. Corti, and F. Sallusto. 2006. Understanding and making use of human memory B cells. *Immunol. Rev.* 211: 303–309.
- Langhorne, J., F. M. Ndungu, A. M. Sponaas, and K. Marsh. 2008. Immunity to malaria: more questions than answers. *Nat. Immunol.* 9: 725–732.
- Cagigi, A., A. Nilsson, A. De Milito, and F. Chiodi. 2008. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. *Vaccine* 26: 3016–3025.
- Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. *J. Immunol.* 171: 4969–4973.
- Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. *Nat. Med.* 9: 1131–1137.
- el-Ad, B., Y. Roth, A. Winder, Z. Tochner, T. Lublin-Tennenbaum, E. Katz, and T. Schwartz. 1990. The persistence of neutralizing antibodies after revaccination against smallpox. *J. Infect. Dis.* 161: 446–448.
- Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. *N. Engl. J. Med.* 357: 1903–1915.
- Mamani-Matsuda, M., A. Cosma, S. Weller, A. Faili, C. Staib, L. Garcon, O. Hermine, O. Beyne-Rauzy, C. Fieschi, J. O. Pers, et al. 2008. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. *Blood* 111: 4653–4659.

11. Nanan, R., D. Heinrich, M. Frosch, and H. W. Kreth. 2002. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. *Vaccine* 20: 498–504.
12. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. *Science* 298: 2199–2202.
13. Chiron, D., I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego. 2008. Toll-like receptors: lessons to learn from normal and malignant human B cells. *Blood* 112: 2205–2213.
14. Quinn, C. P., P. M. Dull, V. Semenova, H. Li, S. Crotty, T. H. Taylor, E. Steward-Clark, K. L. Stamey, D. S. Schmidt, K. W. Stinson, et al. 2004. Immune responses to *Bacillus anthracis* protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. *J. Infect. Dis.* 190: 1228–1236.
15. Blanchard Rohner, G., M. D. Snape, D. F. Kelly, T. John, A. Morant, L. M. Yu, A. Borkowski, F. Ceddia, R. Borrow, C. A. Siegrist, and A. J. Pollard. 2008. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. *J. Immunol.* 180: 2165–2173.
16. Leyendeckers, H., M. Odendahl, A. Lohndorf, J. Irsch, M. Spangfort, S. Miltenyi, N. Hunzelmann, M. Assenmacher, A. Radbruch, and J. Schmitz. 1999. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. *Eur. J. Immunol.* 29: 1406–1417.
17. van der Kolk, L. E., J. W. Baars, M. H. Prins, and M. H. van Oers. 2002. Rituximab treatment results in impaired secondary humoral immune responsiveness. *Blood* 100: 2257–2259.
18. McLaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J. Clin. Oncol.* 16: 2825–2833.
19. Davis, T. A., A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy. 2000. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. *J. Clin. Oncol.* 18: 3135–3143.
20. Cambridge, G., M. J. Leandro, J. C. Edwards, M. R. Ehrenstein, M. Salden, M. Bodman-Smith, and A. D. Webster. 2003. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. *Arthritis Rheum.* 48: 2146–2154.
21. Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. *Nat. Rev. Drug Discov.* 5: 471–484.
22. Halperin, S. A., G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J. J. Eiden. 2003. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. *Vaccine* 21: 2461–2467.
23. Halperin, S. A., S. Dobson, S. McNeil, J. M. Langley, B. Smith, R. McCall-Sani, D. Levitt, G. V. Nest, D. Gennevois, and J. J. Eiden. 2006. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. *Vaccine* 24: 20–26.
24. Mullen, G. E., R. D. Ellis, K. Miura, E. Malkin, C. Nolan, M. Hay, M. P. Fay, A. Saul, D. Zhu, K. Rausch, et al. 2008. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for *Plasmodium falciparum* malaria. *PLoS ONE* 3: e2940.
25. Crotty, S., R. D. Aubert, J. Glidewell, and R. Ahmed. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. *J. Immunol. Methods* 286: 111–122.
26. Liang, K. Y., and S. L. Zeger. 1986. Longitudinal data analysis using generalized linear models. *Biometrika* 73: 13–22.
27. Wrammert, J., K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N. Y. Zheng, I. Mays, L. Garman, C. Helms, J. James, G. M. Air, J. D. Capra, R. Ahmed, and P. C. Wilson. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. *Nature* 453: 667–671.
28. Sasaki, S., X. S. He, T. H. Holmes, C. L. Dekker, G. W. Kemble, A. M. Arvin, and H. B. Greenberg. 2008. Influence of prior influenza vaccination on antibody and B-cell responses. *PLoS ONE* 3: e2975.
29. Bernasconi, N. L., N. Onai, and A. Lanzavecchia. 2003. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. *Blood* 101: 4500–4504.
30. Hand, T. W., and S. M. Kaech. 2008. Intrinsic and extrinsic control of effector T cell survival and memory T cell development. *Immunol. Res. In press.*
31. Odendahl, M., H. Mei, B. F. Hoyer, A. M. Jacobi, A. Hansen, G. Muehlinghaus, C. Berek, F. Hiepe, R. Manz, A. Radbruch, and T. Dörner. 2005. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. *Blood* 105: 1614–1621.
32. Eisenbarth, S. C., O. R. Colegio, W. O'Connor, F. S. Sutterwala, and R. A. Flavell. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. *Nature* 453: 1122–1126.
33. Crompton, P. D., B. Traore, K. Kayentao, S. Doumbo, A. Ongoiba, S. A. Diakite, M. A. Krause, D. Doumtabe, Y. Kone, G. Weiss, et al. 2008. Sick cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. *J. Infect. Dis.* 198: 1265–1275.